Nanoparticle Drug Delivery Systems for Synergistic Delivery of Tumor Therapy

Overview

Journal Front Pharmacol

Date 2023 Mar 6

PMID 36874010

Authors

Daoyuan Chen

Xuecun Liu

Xiaoyan Lu

Jingwei Tian

Affiliations

Soon will be listed here.

Abstract

Nanoparticle drug delivery systems have proved anti-tumor effects; however, they are not widely used in tumor therapy due to insufficient ability to target specific sites, multidrug resistance to anti-tumor drugs, and the high toxicity of the drugs. With the development of RNAi technology, nucleic acids have been delivered to target sites to replace or correct defective genes or knock down specific genes. Also, synergistic therapeutic effects can be achieved for combined drug delivery, which is more effective for overcoming multidrug resistance of cancer cells. These combination therapies achieve better therapeutic effects than delivering nucleic acids or chemotherapeutic drugs alone, so the scope of combined drug delivery has also been expanded to three aspects: drug-drug, drug-gene, and gene-gene. This review summarizes the recent advances of nanocarriers to co-delivery agents, including i) the characterization and preparation of nanocarriers, such as lipid-based nanocarriers, polymer nanocarriers, and inorganic delivery carriers; ii) the advantages and disadvantages of synergistic delivery approaches; iii) the effectual delivery cases that are applied in the synergistic delivery systems; and iv) future perspectives in the design of nanoparticle drug delivery systems to co-deliver therapeutic agents.

Citing Articles

Recent advances in the bench-to-bedside translation of cancer nanomedicines.

Liu Y, Zhang Y, Li H, Hu T Acta Pharm Sin B. 2025; 15(1):97-122.

PMID: 40041906 PMC: 11873642. DOI: 10.1016/j.apsb.2024.12.007.

Prostate Cancer: De-regulated Circular RNAs With Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Genomics Proteomics. 2025; 22(2):136-165.

PMID: 39993805 PMC: 11880926. DOI: 10.21873/cgp.20494.

Harnessing nanotechnology for cancer treatment.

Zhu J, Lee H, Huang R, Zhou J, Zhang J, Yang X Front Bioeng Biotechnol. 2025; 12:1514890.

PMID: 39902172 PMC: 11788409. DOI: 10.3389/fbioe.2024.1514890.

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.

Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M Front Immunol. 2025; 15:1479483.

PMID: 39850897 PMC: 11754201. DOI: 10.3389/fimmu.2024.1479483.

Phytonanoparticles as novel drug carriers for enhanced osteogenesis and osseointegration.

Suresh N, Thomas N, Mauramo M, Waltimo T, Sorsa T, Anil S Discov Nano. 2025; 20(1):11.

PMID: 39821381 PMC: 11739449. DOI: 10.1186/s11671-024-04164-9.

References

Chen W, Luo G, Qiu W, Lei Q, Liu L, Wang S . Mesoporous silica-based versatile theranostic nanoplatform constructed by layer-by-layer assembly for excellent photodynamic/chemo therapy. Biomaterials. 2016; 117:54-65. DOI: 10.1016/j.biomaterials.2016.11.057. View

Liu B, Han L, Liu J, Han S, Chen Z, Jiang L . Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomedicine. 2017; 12:955-968. PMC: 5293363. DOI: 10.2147/IJN.S115136. View

Li Y, Chua M, Kunnath A, Chowdhury E . Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Int J Nanomedicine. 2012; 7:2473-81. PMC: 3373294. DOI: 10.2147/IJN.S30500. View

Tapeinos C, Battaglini M, Ciofani G . Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017; 264:306-332. PMC: 6701993. DOI: 10.1016/j.jconrel.2017.08.033. View

Lungwitz U, Breunig M, Blunk T, Gopferich A . Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005; 60(2):247-66. DOI: 10.1016/j.ejpb.2004.11.011. View

Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T . Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014; 194:228-37. DOI: 10.1016/j.jconrel.2014.09.005. View

Yin T, Liu Y, Yang M, Wang L, Zhou J, Huo M . Novel Chitosan Derivatives with Reversible Cationization and Hydrophobicization for Tumor Cytoplasm-Specific Burst Co-delivery of siRNA and Chemotherapeutics. ACS Appl Mater Interfaces. 2020; 12(13):14770-14783. DOI: 10.1021/acsami.9b19373. View

Fan J, Cheng Y, Sun M . Functionalized Gold Nanoparticles: Synthesis, Properties and Biomedical Applications. Chem Rec. 2020; 20(12):1474-1504. DOI: 10.1002/tcr.202000087. View

Yang H, Villani R, Wang H, Simpson M, Roberts M, Tang M . The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018; 37(1):266. PMC: 6211502. DOI: 10.1186/s13046-018-0909-x. View

10.

Yu H, Lee H, Herrmann A, Buettner R, Jove R . Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-46. DOI: 10.1038/nrc3818. View

11.

Yang H, Lu Y, Lin K, Hsu S, Huang C, She S . EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy. Biomaterials. 2013; 34(29):7204-14. DOI: 10.1016/j.biomaterials.2013.06.007. View

12.

Luo K, Gao Y, Yin S, Yao Y, Yu H, Wang G . Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer. Acta Biomater. 2021; 134:649-663. DOI: 10.1016/j.actbio.2021.07.029. View

13.

Zhang R, Wei S, Shao L, Tong L, Wu Y . Imaging Intracellular Drug/siRNA Co-Delivery by Self-Assembly Cross-Linked Polyethylenimine with Fluorescent Core-Shell Silica Nanoparticles. Polymers (Basel). 2022; 14(9). PMC: 9102585. DOI: 10.3390/polym14091813. View

14.

Swift L, Rephaeli A, Nudelman A, Phillips D, Cutts S . Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 2006; 66(9):4863-71. DOI: 10.1158/0008-5472.CAN-05-3410. View

15.

Zhu F, Tan G, Zhong Y, Jiang Y, Cai L, Yu Z . Smart nanoplatform for sequential drug release and enhanced chemo-thermal effect of dual drug loaded gold nanorod vesicles for cancer therapy. J Nanobiotechnology. 2019; 17(1):44. PMC: 6437988. DOI: 10.1186/s12951-019-0473-3. View

16.

Sriraman S, Geraldo V, Luther E, Degterev A, Torchilin V . Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. J Control Release. 2015; 220(Pt A):160-168. PMC: 4688222. DOI: 10.1016/j.jconrel.2015.10.037. View

17.

Uddin M, Balaravi Pillai B, Tha K, Ashaie M, Karim M, Chowdhury E . Carbonate Apatite Nanoparticles-Facilitated Intracellular Delivery of siRNA(s) Targeting Calcium Ion Channels Efficiently Kills Breast Cancer Cells. Toxics. 2018; 6(3). PMC: 6161028. DOI: 10.3390/toxics6030034. View

18.

Lobatto M, Fuster V, Fayad Z, Mulder W . Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov. 2011; 10(11):835-52. PMC: 3623275. DOI: 10.1038/nrd3578. View

19.

Dong S, Zhou X, Yang J . TAT modified and lipid - PEI hybrid nanoparticles for co-delivery of docetaxel and pDNA. Biomed Pharmacother. 2016; 84:954-961. DOI: 10.1016/j.biopha.2016.10.003. View

20.

Vangijzegem T, Stanicki D, Laurent S . Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opin Drug Deliv. 2018; 16(1):69-78. DOI: 10.1080/17425247.2019.1554647. View